Altimmune (ALT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ALT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.…

Altimmune remains a 'Sell' as pemvidutide lacks clear differentiation in the competitive MASH landscape and faces significant funding challenges. ALT's share count has doubled year-over-year, with further dilution likely…

Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript…

Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration on a potential phase…

Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD …

Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile…

Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolera…

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)…

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver dise…

Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, …

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature n…

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, …

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that manageme…

Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strengt…

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?…

New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the Alpha Liquid Terminal ("ALTx"), today announced the relaunch of its platform as the ALT/X Compute Terminal , refocusing…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

